Siga Technologies Inc. (SIGA)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
SIGA Technologies, Inc. (SIGA) Q2 2026 Earnings Call Transcript
SIGA Technologies, Inc. (SIGA) Q2 2026 Earnings Call Transcript
Siga Technologies Q2 Earnings Call Highlights
Siga Technologies NASDAQ: SIGA reported second-quarter product-related revenue of $38 million, driven primarily by deliveries of intravenous TPOXX to the U.S. Strategic National Stockpile and oral TPOXX sales to international customers. The company said the quarter reflected the variable timing of its government-focused procurement business after minimal product revenue in the first quarter.
Siga Technologies Q1 Earnings Call Highlights
Siga Technologies NASDAQ: SIGA reported a first-quarter loss as product deliveries remained minimal, but management said it expects a pickup in the second quarter tied to an international order and additional deliveries to the U.S. Strategic National Stockpile.
Siga Technologies Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 391 | $2,232.16 | $1,178.86 | -$1,053.3 | -47.19% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 15,534 | $56,550 | $46,923.55 | -$9,626.45 | -17.02% |
| HL Howard Lu FIRST WILSHIRE SECURITIES MANAGEMENT Inc. | 1.34M | $7.4M | $4.04M | -$3.36M | -45.43% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 128 | $684.8 | $386.56 | -$298.24 | -43.55% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 1,133 | $5,382.13 | $3,455.65 | -$1,926.48 | -35.79% |
Siga Technologies Inc. (SIGA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Siga Technologies Inc. ever had a stock split?
Siga Technologies Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Diem Nguyen CEO | NASDAQ (NMS) Exchange | 826917106 CUSIP |
| US Country | 49 Employees | 7 Apr 2026 Last Dividend | - Last Split | 9 Sep 1997 IPO Date |
Overview
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company with a specific focus on health security markets within the United States. Incorporated in 1995, the company has established its headquarters in New York, New York. SIGA Technologies is dedicated to the development, manufacture, and commercialization of solutions for serious conditions and diseases that affect health security. The core mission of SIGA revolves around enhancing preparedness and response capabilities against biological threats, thereby contributing significantly to public health defense mechanisms.
Products and Services
TPOXX (tecovirimat)
SIGA Technologies' flagship product is TPOXX, an antiviral medication that is taken orally. TPOXX has been specifically developed for the treatment of human smallpox disease caused by the variola virus. This drug represents a significant advancement in the field of biodefense, offering a critical tool in the event of a smallpox outbreak. Its approval and availability highlight SIGA’s pivotal role in enhancing national and global preparedness against potential bioterrorism or naturally occurring outbreaks of this deadly virus.
